This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Helicos BioSciences Expands Its License With Arizona Technology Enterprises Covering Next Generation Sequencing; New Patents Continue To Issue

Stocks in this article: HLCS

Helicos BioSciences Corporation (OTCQB: HLCS.PK) announced today that it has amended its existing license with Arizona Technology Enterprises (AzTE) to include all activities that fall within the scope of, or constitute the practice of, the licensed patents, and gives Helicos full and unencumbered rights to the associated intellectual property. The license, which gives Helicos rights to several patents covering sequencing-by-synthesis methods, now expressly includes detection methods that do not rely on optically-labeled nucleotides.

“The expanded license is another example of Helicos’s successful strategy of systematically expanding its IP portfolio. The newly acquired rights will be an important asset in our licensing and IP monetization efforts that include the active litigation announced previously.” stated Dr. Ivan Trifunovich, President and CEO of Helicos. “In addition to the expanded license, Helicos continues to increase the depth and breadth of company’s patent estate through newly issued patents and a large number of important patent applications in process. As we witness the rapid expansion of next generation sequencing applications covered by our patents in the research and molecular diagnostic (MDx) fields, we intend to maximize the return to our stakeholders through a licensing program and IP enforcement mechanisms.” continued Dr. Trifunovich.

In 2011, 8 Helicos’s patents were issued or allowed, and more than a dozen patent applications were filed. For example, U.S. patent No. 7,875,440 (currently the subject of an inter parties reexamination by the USPTO based upon the request of Life Technologies Corporation), entitled “Method of determining the nucleotide sequence of oligonucleotides and DNA molecules”, which derives from an existing foundational invention with a very early priority date of May 1998, and U.S. patent No. 7,897,345 entitled “Short Cycle Methods for Sequencing Polynucleotides”. Both patents contain very broad claims that cover the very core chemistry of most major next generation sequencing platforms. Another example is U.S. patent 7,948,625, titled “Apparatus and Methods for Analyzing Samples”, which covers instrument claims on a lighting system for detecting samples that includes 2 light sources.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs